NV5 logo

AcuCort BST:NV5 Stock Report

Last Price

€0.048

Market Cap

€7.7m

7D

9.2%

1Y

n/a

Updated

25 Dec, 2024

Data

Company Financials

NV5 Stock Overview

Develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. More details

NV5 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

AcuCort AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for AcuCort
Historical stock prices
Current Share PriceSEK 0.048
52 Week HighSEK 0.091
52 Week LowSEK 0.04
Beta1.13
1 Month Change-16.20%
3 Month Change-34.62%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-25.86%

Recent News & Updates

Recent updates

Shareholder Returns

NV5DE PharmaceuticalsDE Market
7D9.2%-1.7%-1.6%
1Yn/a-15.8%6.8%

Return vs Industry: Insufficient data to determine how NV5 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how NV5 performed against the German Market.

Price Volatility

Is NV5's price volatile compared to industry and market?
NV5 volatility
NV5 Average Weekly Movement13.1%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: NV5's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: NV5's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20063Jonas Jonmarkwww.acucort.com

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

AcuCort AB (publ) Fundamentals Summary

How do AcuCort's earnings and revenue compare to its market cap?
NV5 fundamental statistics
Market cap€7.70m
Earnings (TTM)-€1.23m
Revenue (TTM)€608.55k

12.6x

P/S Ratio

-6.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NV5 income statement (TTM)
RevenueSEK 7.01m
Cost of RevenueSEK 15.54m
Gross Profit-SEK 8.53m
Other ExpensesSEK 5.68m
Earnings-SEK 14.21m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.12
Gross Margin-121.67%
Net Profit Margin-202.70%
Debt/Equity Ratio0%

How did NV5 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 15:21
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AcuCort AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution